Novartis AG
NVS111.420USD
+0.840+0.76%
Close 03/05, 16:00（ET）Quotes delayed by 15 min
220.06BMarket Cap
18.43P/E TTM
More Details of Novartis AG Company
Company Info
Company codeNVS
Company nameNovartis AG
IPO dateMay 07, 2001
Founded at1996
CEODr. Vasant (Vas) Narasimhan, M.D.
Number of employees75883
Security typeOrdinary Share
Fiscal year-endMay 07
AddressLichtstrasse 35
CityBASEL
Stock exchangeJohannesburg Stock Exchange
CountrySwitzerland
Postal code4056
Phone41613241111
Websitehttps://www.novartis.com/
Company codeNVS
IPO dateMay 07, 2001
Founded at1996
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Patrick Horber, M.D.
Mr. Patrick Horber, M.D.
President - International, Member of the Executive Committee
President - International, Member of the Executive Committee
--
--
Ms. Ana de Pro Gonzalo
Ms. Ana de Pro Gonzalo
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Charles L. Sawyers, M.D.
Dr. Charles L. Sawyers, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John D. Young
Mr. John D. Young
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Robert (Rob) Kowalski
Dr. Robert (Rob) Kowalski
Chief People and Organization Officer, Member of the Executive Committee
Chief People and Organization Officer, Member of the Executive Committee
--
--
Dr. Fiona H. Marshall, Ph.D.
Dr. Fiona H. Marshall, Ph.D.
President - Biomedical Research, Member of the Executive Committee
President - Biomedical Research, Member of the Executive Committee
--
--
Dr. Shreeram Aradhye, M.D.
Dr. Shreeram Aradhye, M.D.
President - Global Drug Development and Chief Medical Officer, Member of the Executive Committee
President - Global Drug Development and Chief Medical Officer, Member of the Executive Committee
--
--
Dr. Simon E. Moroney
Dr. Simon E. Moroney
Independent Non-Executive Vice Chairman of the Board
Independent Non-Executive Vice Chairman of the Board
--
--
Ms. Karen L. Hale
Ms. Karen L. Hale
Chief Legal Officer, Member of the Executive Committee
Chief Legal Officer, Member of the Executive Committee
--
--
Dr. Steffen Lang, Ph.D.
Dr. Steffen Lang, Ph.D.
President - Operations, Member of the Executive Committee
President - Operations, Member of the Executive Committee
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Patrick Horber, M.D.
Mr. Patrick Horber, M.D.
President - International, Member of the Executive Committee
President - International, Member of the Executive Committee
--
--
Ms. Ana de Pro Gonzalo
Ms. Ana de Pro Gonzalo
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Charles L. Sawyers, M.D.
Dr. Charles L. Sawyers, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John D. Young
Mr. John D. Young
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Robert (Rob) Kowalski
Dr. Robert (Rob) Kowalski
Chief People and Organization Officer, Member of the Executive Committee
Chief People and Organization Officer, Member of the Executive Committee
--
--
Dr. Fiona H. Marshall, Ph.D.
Dr. Fiona H. Marshall, Ph.D.
President - Biomedical Research, Member of the Executive Committee
President - Biomedical Research, Member of the Executive Committee
--
--
Revenue Breakdown
Currency: USDUpdate time: Wed, Mar 5
Currency: USDUpdate time: Wed, Mar 5
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Rest of portfolio
10.07B
20.01%
Cardiovascular, Renal and Metabolism - Entresto
7.82B
15.54%
Immunology - Cosentyx
6.14B
12.20%
Neuroscience - Kesimpta
3.22B
6.40%
Oncology -Kisqali
3.03B
6.02%
Other
20.02B
39.79%
By RegionUSD
Name
Revenue
Proportion
United States
21.14B
42.02%
Other Foreign-
18.51B
36.79%
China
3.89B
7.73%
Germany
3.66B
7.27%
France
1.79B
3.56%
Switzerland
1.31B
2.61%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Rest of portfolio
10.07B
20.01%
Cardiovascular, Renal and Metabolism - Entresto
7.82B
15.54%
Immunology - Cosentyx
6.14B
12.20%
Neuroscience - Kesimpta
3.22B
6.40%
Oncology -Kisqali
3.03B
6.02%
Other
20.02B
39.79%
Shareholder
Update time: Fri, Feb 21
Update time: Fri, Feb 21
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Dodge & Cox
0.61%
PRIMECAP Management Company
0.55%
Dimensional Fund Advisors, L.P.
0.41%
Loomis, Sayles & Company, L.P.
0.28%
Franklin Mutual Advisers, LLC
0.21%
Other
97.91%
Shareholder Statistics
Shareholder
Proportion
Dodge & Cox
0.61%
PRIMECAP Management Company
0.55%
Dimensional Fund Advisors, L.P.
0.41%
Loomis, Sayles & Company, L.P.
0.28%
Franklin Mutual Advisers, LLC
0.21%
Other
97.91%
Type
Shareholder
Proportion
Investment Advisor
3.30%
Investment Advisor/Hedge Fund
2.63%
Research Firm
0.34%
Hedge Fund
0.28%
Bank and Trust
0.12%
Holding Company
0.04%
Pension Fund
0.02%
Other
93.22%
Institutional Shareholding
Update time: Thu, Feb 20
Update time: Thu, Feb 20
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
1868
133.88M
6.78%
-8.72M
2024Q4
1926
133.99M
6.78%
-9.23M
2024Q3
1858
134.89M
6.74%
-11.71M
2024Q2
1840
139.20M
6.87%
-9.16M
2024Q1
1808
141.29M
6.92%
-7.92M
2023Q4
1811
141.98M
6.94%
-15.97M
2023Q3
1775
150.91M
7.33%
-7.18M
2023Q2
1759
150.73M
7.28%
-24.14M
2023Q1
1762
167.48M
7.98%
-13.01M
2022Q4
1782
173.67M
8.19%
-17.14M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Dodge & Cox
12.21M
0.61%
-7.21K
-0.05%
Dec 31, 2024
PRIMECAP Management Company
11.02M
0.55%
-983.01K
-8.18%
Dec 31, 2024
Dimensional Fund Advisors, L.P.
8.18M
0.41%
+90.82K
+1.12%
Dec 31, 2024
Loomis, Sayles & Company, L.P.
5.57M
0.28%
-192.67K
-3.33%
Dec 31, 2024
Franklin Mutual Advisers, LLC
4.26M
0.21%
-16.98K
-0.39%
Dec 31, 2024
Wellington Management Company, LLP
3.64M
0.18%
-351.31K
-8.78%
Dec 31, 2024
Morgan Stanley Smith Barney LLC
3.59M
0.18%
-52.88K
-1.45%
Dec 31, 2024
Parametric Portfolio Associates LLC
2.97M
0.15%
-86.17K
-2.81%
Dec 31, 2024
Renaissance Technologies LLC
2.66M
0.13%
+368.17K
+16.00%
Dec 31, 2024
Managed Account Advisors LLC
2.55M
0.12%
-164.18K
-6.03%
Dec 31, 2024
View more
Related ETFs
Update time: Wed, Mar 5
Update time: Wed, Mar 5
Name
Proportion
VanEck Pharmaceutical ETF
4.92%
Amplify International Enhanced Dividend Income ETF
2.91%
Invesco International Dividend Achievers ETF
2.54%
Altrius Global Dividend ETF
2.31%
SGI Enhanced Global Income ETF
2.31%
Pacer Global Cash Cows Dividend ETF
1.98%
Avantis International Large Cap Value ETF
1.85%
Brandes International ETF
1.48%
SP Funds S&P World (ex-US) ETF
1.42%
Pacer Trendpilot International ETF
1.22%
View more
VanEck Pharmaceutical ETF
Proportion4.92%
Amplify International Enhanced Dividend Income ETF
Proportion2.91%
Invesco International Dividend Achievers ETF
Proportion2.54%
Altrius Global Dividend ETF
Proportion2.31%
SGI Enhanced Global Income ETF
Proportion2.31%
Pacer Global Cash Cows Dividend ETF
Proportion1.98%
Avantis International Large Cap Value ETF
Proportion1.85%
Brandes International ETF
Proportion1.48%
SP Funds S&P World (ex-US) ETF
Proportion1.42%
Pacer Trendpilot International ETF
Proportion1.22%
Dividend
A total of
36.74B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Feb 12, 2024
NVS.NB Final Cash Dividend of gross USD 3.739544 paid on Apr 19, 2024 going ex on Mar 07, 2024
Mar 08, 2024
Apr 19, 2024
Mar 07, 2024
Feb 02, 2023
NVS.NB Final Cash Dividend of gross USD 3.498699 paid on Mar 20, 2023 going ex on Mar 09, 2023
Mar 10, 2023
Mar 20, 2023
Mar 09, 2023
Feb 04, 2022
NVS.NB Final Cash Dividend of gross USD 3.32525 paid on Mar 17, 2022 going ex on Mar 08, 2022
Mar 09, 2022
Mar 17, 2022
Mar 08, 2022
Jan 26, 2021
NVS.NB Final Cash Dividend of gross USD 3.199072 paid on Mar 15, 2021 going ex on Mar 04, 2021
Mar 05, 2021
Mar 15, 2021
Mar 04, 2021
Jan 31, 2020
NVS.NB Final Cash Dividend of gross USD 3.087366 paid on Mar 12, 2020 going ex on Mar 03, 2020
Mar 04, 2020
Mar 12, 2020
Mar 03, 2020
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data